NASDAQ · Key Statistics

Churchill Capital Corp. Xii (CXII) P/E Ratio, ROE & Key Statistics

$10.39 NASDAQ: CXII Market Cap $433.78M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Churchill Capital Corp. Xii (CXII), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/B ratioShare price divided by book value per share.1.45

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.4.41

Per share and size

MetricValue
Book value per shareShareholders’ equity divided by shares outstanding.$0.00
Market capitalisationShare price times shares outstanding.$433.78M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Churchill Capital Corp. Xii (CXII) statistics — frequently asked questions

How much debt does Churchill Capital Corp. Xii carry?

Churchill Capital Corp. Xii (CXII) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.

P/E and ROE of other Shell Companies stocks

GTEN P/E 117.02TLNC P/E 45.18All Shell Companies stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.